Breakthroughs with cell and gene therapy innovation are transforming the therapeutic landscape, with a number of approvals in the US and EU and more in the pipeline. This issue has been top of mind during many sessions throughout Cencora’s two-day ThinkLive CGT Summit. In this impactful meeting, Cencora’s Lung-I Cheng, Ph.D., Vice President and Head of Cell and Gene Therapy, joined Rita Johnson-Greene, Chief Operating Officer, Alliance for Regenerative Medicine (ARM) to reflect on the current and future state of CGT innovation.